Regulation Of Pulmonary Immune Responses To Subunit Vaccines Against Tuberculosis
Funder
National Health and Medical Research Council
Funding Amount
$509,202.00
Summary
Tuberculosis (TB) remains an enormous health problem world-wide. Improving the effectiveness of anti-TB vaccines is essential for its control. The first approach to improving subunit TB vaccines will be to manipulate the cellular immune response to the vaccine by increasing the positive cytokine signals, or reducing inhibitory effects on the immune response. The second approach is to develop new subunit vaccines to deliver to the lung in order to increase the potency of the protective response.
Development Of New Therapies For Respiratory Diseases And Infection
Funder
National Health and Medical Research Council
Funding Amount
$847,490.00
Summary
Prof Hansbro’s group have developed world 1st experimental models of emphysema, severe asthma infection and lung cancer. He uses them to further our understanding of these untreatable diseases. This has led to the development of new potential therapeutic approaches. Now, in discovery programs he will expand studies of pathogenesis to identify new therapeutic targets these diseases. In development and translational programs he will progress new therapies towards clinical application.
High Flow Cannula Therapy In Bronchiolitis, A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,283,342.00
Summary
Bronchiolitis is the leading cause of paediatric hospitalisation in Australia. Despite multiple research studies the outcome has not changed. Our recent studies supported by other international studies have shown that the use of high flow nasal cannula oxygen may reduce the severity and prevent progression of the disease. We aim to investigate if HFNC in regional hospitals can reduce the number of infants transferred to specialist children’s hospitals and reduce the socio-economic burden.
The Emerging Problem Of Non-tuberculous Mycobacteria Infection: Understanding Aetiology, Geospatial Epidemiology And Developing Interventions
Funder
National Health and Medical Research Council
Funding Amount
$988,791.00
Summary
This project will be largest study of non-tuberculous mycobacterial (NTM) infection in cystic fibrosis. By combining growing the bacteria with detailed information from the CF patient data registry, geographical location and environmental conditions, this study will provide novel insights into factors associated with NTM. Gene sequencing and airway infection profiling will extend understanding and has the potential to identify novel risk factors and biomarkers for NTM-related airways disease.
How The Immune Response Can Affect Influenza Virus And Asthma
Funder
National Health and Medical Research Council
Funding Amount
$333,964.00
Summary
A strong immune response is essential for protection against viral infections. However, in some circumstances a strong immune response against viruses can actually further aggravate disease. In addition, an anti-viral immune response can trigger asthma attacks in allergic individuals. This research thus seeks to understand and therefore mitigate the potentially detrimental role of inflammation in influenza virus infections and asthma.
Characterisation Of A Novel Signaling Network That Translates Early-life Respiratory Infection Into Chronic Lung Disease
Funder
National Health and Medical Research Council
Funding Amount
$316,449.00
Summary
Bacterial and viral respiratory infections in early-life cause permanent damage to the lungs and reduce lung function in later life. They may also increase the risk of developing asthma and emphysema. These are substantial health problems in Australia. My project aims to identify how infections cause these effects. This will enable me to identify new therapeutic targets and develop new therapies for the prevention of chronic lung diseases.
The Role Of Long Non-coding RNA In Regulating Lung Immunity And Inflammation
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
Chronic inflammatory diseases of the lung, asthma and COPD, account for significant morbidity and poor quality of life in our community. Respiratory infection is one of the major causes of exacerbation and affects 50-80% of both asthma and COPD patients admitted to hospital. These groups of patients are steroid resistance and difficult to manage. Our aim is to identify novel molecules important in regulating inflammation and to target them therapeutically to treat these patients.
Long Term Outcomes Following Early Infection And Inflammation In Cystic Fibrosis Lung Disease
Funder
National Health and Medical Research Council
Funding Amount
$75,006.00
Summary
This study involves the long-term follow up of birth cohort of 98 infants with cystic fibrosis, with the objectives of assessing the impact of lower airway infection and inflammation in infancy and early childhood on the development of CF lung disease over 20-25 years, and of describing the development of the lower airway microbiota in early CF lung disease and its relationship to clinical outcomes.
Inhibition Of IFN-?/? By Human Metapneumovirus And The Induction Of Inflammation
Funder
National Health and Medical Research Council
Funding Amount
$605,251.00
Summary
The newly isolated human metapneumovirus (hMPV) causes significant respiratory illness in infants, young children and the elderly. The virus can persist long-term and may predispose individuals to chronic lung disease. This proposal aims to determine the mechanisms by which hMPV infection causes respiratory disease, with a view to improving treatments and preventing disease.